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Recommended Immunization Schedules
for Persons Aged 0–18 Years —
United States, 2007
The Advisory Committee on Immunization Practices
(ACIP) periodically reviews the recommended immunization
schedule for persons aged 0–18 years to ensure that the sched-
ule is current with changes in vaccine formulations and
reflects revised recommendations for the use of licensed vac-
cines, including those newly licensed.
The changes to the previous childhood and adolescent
immunization schedule, published January 2006 (1), are as
follows:
• The new rotavirus vaccine (Rota) is recommended in a
3-dose schedule at ages 2, 4, and 6 months. The first dose
should be administered at ages 6 weeks through 12 weeks
with subsequent doses administered at 4–10 week inter-
vals. Rotavirus vaccination should not be initiated for
infants aged >12 weeks and should not be administered
after age 32 weeks (2).
• The influenza vaccine is now recommended for all chil-
dren aged 6–59 months (3).
• Varicella vaccine recommendations are updated. The first
dose should be administered at age 12–15 months, and a
newly recommended second dose should be administered
at age 4–6 years (4).
• The new human papillomavirus vaccine (HPV) is rec-
ommended in a 3-dose schedule with the second and third
doses administered 2 and 6 months after the first dose.
Routine vaccination with HPV is recommended for
females aged 11–12 years; the vaccination series can be
started in females as young as age 9 years; and a catch-up
vaccination is recommended for females aged 13–26 years
who have not been vaccinated previously or who have
not completed the full vaccine series (5).
• The main change to the format of the schedule is the
division of the recommendation into two schedules: one
schedule for persons aged 0–6 years (Figure 1) and
another for persons aged 7–18 years (Figure 2). Special
populations are represented with purple bars; the
11–12 years assessment is emphasized with the bold, capi-
talized fonts in the title of that column. Rota, HPV, and
varicella vaccines are incorporated in the catch-up
immunization schedule (Table).
Vaccine Information Statements
The National Childhood Vaccine Injury Act requires that
health-care providers provide parents or patients with copies
of Vaccine Information Statements before administering each
dose of the vaccines listed in the schedule. Additional infor-
mation is available from state health departments and from
CDC at http://www.cdc.gov/nip/publications/vis.
Detailed recommendations for using vaccines are available
from package inserts, ACIP statements on specific vaccines,
and the 2003 Red Book (6). ACIP statements for each recom-
mended childhood vaccine are available from CDC at
http://www.cdc.gov/nip/publications/acip-list.htm. In
addition, guidance for obtaining and completing a Vaccine
Adverse Event Reporting System form is available at http://
www.vaers.hhs.gov or by telephone, 800-822-7967.
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The recommended immunization schedules for persons aged 0–18 years and the catch-
up immunization schedule for 2007 have been approved by the Advisory Committee
on Immunization Practices, the American Academy of Pediatrics, and the American
Academy of Family Physicians. The standard MMWR footnote format has been modified
for publication of this schedule.
Suggested citation: Centers for Disease Control and Prevention. Recommended
immunization schedules for persons aged 0–18 years—United States, 2007. MMWR
2006;55(51&52):Q1–Q4.
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This schedule indicates the recommended ages for routine administration of currently
licensed childhood vaccines, as of December 1, 2006, for children aged 0–6 years.
Additional information is available at http://www.cdc.gov/nip/recs/child-schedule.htm.
Any dose not administered at the recommended age should be administered at any
subsequent visit, when indicated and feasible. Additional vaccines may be licensed
and recommended during the year. Licensed combination vaccines may be used
whenever any components of the combination are indicated and other components
FIGURE 1. Recommended immunization schedule for persons aged 0–6 years — United States, 2007
The Recommended Immunization Schedules for Persons Aged 0–18 Years are approved by the Advisory Committee on Immunization Practices (http://www.cdc.gov/nip/acip),













































PCV PCV PCV PCV

















of the vaccine are not contraindicated and if approved by the Food and Drug
Administration for that dose of the series. Providers should consult the respective
Advisory Committee on Immunization Practices statement for detailed
recommendations. Clinically significant adverse events that follow immunization should
be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance
about how to obtain and complete a VAERS form is available at http://www.vaers.
hhs.gov or by telephone, 800-822-7967.
1. Hepatitis B vaccine (HepB). (Minimum age: birth)
At birth:
• Administer monovalent HepB to all newborns before hospital discharge.
• If mother is hepatitis surface antigen (HBsAg)-positive, administer HepB and
0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth.
• If mother’s HBsAg status is unknown, administer HepB within 12 hours of birth.
Determine the HBsAg status as soon as possible and if HBsAg-positive,
administer HBIG (no later than age 1 week).
• If mother is HBsAg-negative, the birth dose can only be delayed with physician’s
order and mothers’ negative HBsAg laboratory report documented in the infant’s
medical record.
After the birth dose:
• The HepB series should be completed with either monovalent HepB or a
combination vaccine containing HepB. The second dose should be administered
at age 1–2 months. The final dose should be administered at age >24 weeks.
Infants born to HBsAg-positive mothers should be tested for HBsAg and antibody
to HBsAg after completion of >3 doses of a licensed HepB series, at age
9–18 months (generally at the next well-child visit).
4-month dose:
• It is permissible to administer 4 doses of HepB when combination vaccines are
administered after the birth dose. If monovalent HepB is used for doses after
the birth dose, a dose at age 4 months is not needed.
2. Rotavirus vaccine (Rota). (Minimum age: 6 weeks)
• Administer the first dose at age 6–12 weeks. Do not start the series later than
age 12 weeks.
• Administer the final dose in the series by age 32 weeks. Do not administer a
dose later than age 32 weeks.
• Data on safety and efficacy outside of these age ranges are insufficient.
3. Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP).
(Minimum age: 6 weeks)
• The fourth dose of DTaP may be administered as early as age 12 months,
provided 6 months have elapsed since the third dose.
• Administer the final dose in the series at age 4–6 years.
4. Haemophilus influenzae  type b conjugate vaccine (Hib). (Minimum age: 6 weeks)
• If PRP-OMP (PedvaxHIB® or ComVax® [Merck]) is administered at ages 2 and
4 months, a dose at age 6 months is not required.
• TriHiBit® (DTaP/Hib) combination products should not be used for primary
immunization but can be used as boosters following any Hib vaccine in children
aged >12 months.
5. Pneumococcal vaccine. (Minimum age: 6 weeks for pneumococcal conjugate
vaccine [PCV]; 2 years for pneumococcal polysaccharide vaccine [PPV])
• Administer PCV at ages 24–59 months in certain high-risk groups. Administer
PPV to children aged >2 years in certain high-risk groups. See MMWR
2000;49(No. RR-9):1–35.
6. Influenza vaccine. (Minimum age: 6 months for trivalent inactivated influenza
vaccine [TIV]; 5 years for live, attenuated influenza vaccine [LAIV])
• All children aged 6–59 months and close contacts of all children aged
0–59 months are recommended to receive influenza vaccine.
• Influenza vaccine is recommended annually for children aged >59 months with
certain risk factors, health-care workers, and other persons (including household
members) in close contact with persons in groups at high risk. See MMWR
2006;55(No. RR-10):1–41.
• For healthy persons aged 5–49 years, LAIV may be used as an alternative to TIV.
• Children receiving TIV should receive 0.25 mL if aged 6–35 months or 0.5 mL if
aged >3 years.
• Children aged <9 years who are receiving influenza vaccine for the first time
should receive 2 doses (separated by >4 weeks for TIV and >6 weeks for LAIV).
7. Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months)
• Administer the second dose of MMR at age 4–6 years. MMR may be administered
before age 4–6 years, provided >4 weeks have elapsed since the first dose and
both doses are administered at age >12 months.
8. Varicella vaccine. (Minimum age: 12 months)
• Administer the second dose of varicella vaccine at age 4–6 years. Varicella
vaccine may be administered before age 4–6 years, provided that >3 months
have elapsed since the first dose and both doses are administered at age
>12 months. If second dose was administered >28 days following the first dose,
the second dose does not need to be repeated.
9. Hepatitis A vaccine (HepA). (Minimum age: 12 months)
• HepA is recommended for all children aged 1 year (i.e., aged 12–23 months).
The 2 doses in the series should be administered at least 6 months apart.
• Children not fully vaccinated by age 2 years can be vaccinated at subsequent visits.
• HepA is recommended for certain other groups of children, including in areas where
vaccination programs target older children. See MMWR 2006;55(No. RR-7):1–23.
10. Meningococcal polysaccharide vaccine (MPSV4). (Minimum age: 2 years)
• Administer MPSV4 to children aged 2–10 years with terminal complement
deficiencies or anatomic or functional asplenia and certain other high-risk groups.
See MMWR 2005;54(No. RR-7):1–21.


















































FIGURE 2. Recommended immunization schedule for persons aged 7–18 years — United States, 2007
The Recommended Immunization Schedules for Persons Aged 0–18 Years are approved by the Advisory Committee on Immunization Practices (http://www.cdc.gov/nip/acip),
the American Academy of Pediatrics (http://www.aap.org), and the American Academy of Family Physicians (http://www.aafp.org).
This schedule indicates the recommended ages for routine administration of currently
licensed childhood vaccines, as of December 1, 2006, for children aged 7–18 years.
Additional information is available at http://www.cdc.gov/nip/recs/child-schedule.htm.
Any dose not administered at the recommended age should be administered at any
subsequent visit, when indicated and feasible. Additional vaccines may be licensed
and recommended during the year. Licensed combination vaccines may be used
whenever any components of the combination are indicated and other components
of the vaccine are not contraindicated and if approved by the Food and Drug
Administration for that dose of the series. Providers should consult the respective
Advisory Committee on Immunization Practices statement for detailed
recommendations. Clinically significant adverse events that follow immunization should
be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance
about how to obtain and complete a VAERS form is available at http://www.vaers.
hhs.gov or by telephone, 800-822-7967.
1. Tetanus and diphtheria toxoids and acellular pertussis vaccine (Tdap).
(Minimum age: 10 years for BOOSTRIX® and 11 years for ADACEL™)
• Administer at age 11–12 years for those who have completed the recommended
childhood DTP/DTaP vaccination series and have not received a tetanus and
diphtheria toxoids vaccine (Td) booster dose.
• Adolescents aged 13–18 years who missed the 11–12 year Td/Tdap booster
dose should also receive a single dose of Tdap if they have completed the
recommended childhood DTP/DTaP vaccination series.
2. Human papillomavirus vaccine (HPV). (Minimum age: 9 years)
• Administer the first dose of the HPV vaccine series to females at age 11–12 years.
• Administer the second dose 2 months after the first dose and the third dose
6 months after the first dose.
• Administer the HPV vaccine series to females at age 13–18 years if not previously
vaccinated.
3. Meningococcal vaccine. (Minimum age: 11 years for meningococcal conjugate
vaccine [MCV4]; 2 years for meningococcal polysaccharide vaccine [MPSV4])
• Administer MCV4 at age 11–12 years and to previously unvaccinated adolescents
at high school entry (at approximately age 15 years).
• Administer MCV4 to previously unvaccinated college freshmen living in
dormitories; MPSV4 is an acceptable alternative.
• Vaccination against invasive meningococcal disease is recommended for children
and adolescents aged >2 years with terminal complement deficiencies or
anatomic or functional asplenia and certain other high-risk groups. See MMWR
2005;54(No. RR-7):1–21. Use MPSV4 for children aged 2–10 years and MCV4
or MPSV4 for older children.
4. Pneumococcal polysaccharide vaccine (PPV). (Minimum age: 2 years)
• Administer for certain high-risk groups. See MMWR 1997;46(No. RR-8):1–24,
and MMWR 2000;49(No. RR-9):1–35.
5. Influenza vaccine. (Minimum age: 6 months for trivalent inactivated influenza
vaccine [TIV]; 5 years for live, attenuated influenza vaccine [LAIV])
• Influenza vaccine is recommended annually for persons with certain risk factors,
health-care workers, and other persons (including household members)
in close contact with persons in groups at high risk. See MMWR 2006;55
(No. RR-10):1–41.
• For healthy persons aged 5–49 years, LAIV may be used as an alternative
to TIV.
• Children aged <9 years who are receiving influenza vaccine for the first time
should receive 2 doses (separated by >4 weeks for TIV and >6 weeks for LAIV).
6. Hepatitis A vaccine (HepA). (Minimum age: 12 months)
• The 2 doses in the series should be administered at least 6 months apart.
• HepA is recommended for certain other groups of children, including in areas
where vaccination programs target older children. See MMWR 2006;55
(No. RR-7):1–23.
7. Hepatitis B vaccine (HepB). (Minimum age: birth)
• Administer the 3-dose series to those who were not previously vaccinated.
• A 2-dose series of Recombivax HB® is licensed for children aged 11–15 years.
8. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 weeks)
• For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth
dose is not necessary if the third dose was administered at age >4 years.
• If both OPV and IPV were administered as part of a series, a total of 4 doses
should be administered, regardless of the child’s current age.
9. Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months)
• If not previously vaccinated, administer 2 doses of MMR during any visit, with
>4 weeks between the doses.
10. Varicella vaccine. (Minimum age: 12 months)
• Administer 2 doses of varicella vaccine to persons without evidence of immunity.
• Administer 2 doses of varicella vaccine to persons aged <13 years at least
3 months apart. Do not repeat the second dose, if administered >28 days after
the first dose.
• Administer 2 doses of varicella vaccine to persons aged >13 years at least
4 weeks apart.
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Vaccine Minimum age for Dose 1 Dose 1 to Dose 2 Dose 2 to Dose 3 Dose 3 to Dose 4 Dose 4 to Dose 5
6 weeks
CATCH-UP SCHEDULE FOR PERSONS AGED 4 MONTHS–6 YEARS
Minimum interval between doses
8 weeks (as final dose)
This dose only necessary 
for children aged 
12 months–5 years 
who received 3 doses 
before age 12 months










8 weeks (as final dose)
This dose only necessary 
for children aged 
12 months–5 years 
who received 3 doses 















12 months 4 weeks















7 years10 4 weeks
9 years 4 weeks 12 weeks
12 months 6 months
Birth 4 weeks
6 weeks 4 weeks 4 weeks
12 months 4 weeks
12 months
8 weeks
(and 16 weeks after first dose)
4 weeks
if first dose administered at age <12 months
8 weeks (as final dose)
if first dose administered at age 12–14 months
No further doses needed
if first dose administered at age >15 months
4 weeks
if first dose administered at age <12 months
and current age <24 months
8 weeks (as final dose)
if first dose administered at age >12 months
or current age 24–59 months
No further doses needed
for healthy children if first dose
administered at age >24 months
3 months
if first dose administered at age <13 years
4 weeks
if first dose administered at age >13 years
8 weeks
if first dose administered at age <12 months 
6 months
if first dose administered at age >12 months 
4 weeks4
if current age <12 months
No further doses needed
if previous dose administered at age >15 months
8 weeks (as final dose)4
if current age >12 months and second 
dose administered at age <15 months
4 weeks
if current age <12 months
8 weeks (as final dose)
if current age >12 months 
No further doses needed
for healthy children if previous dose
administered at age >24 months
4 weeks6
6 months
if first dose administered
at age <12 months 
TABLE. Catch-up immunization schedule for persons aged 4 months–18 years who start late or who are >1 month behind — United States, 2007
1. Hepatitis B vaccine (HepB). (Minimum age: birth)
• Administer the 3-dose series to those who were not previously vaccinated.
• A 2-dose series of Recombivax HB® is licensed for children aged 11–15 years.
2. Rotavirus vaccine (Rota). (Minimum age: 6 weeks)
• Do not start the series later than age 12 weeks.
• Administer the final dose in the series by age 32 weeks. Do not administer a
dose later than age 32 weeks.
• Data on safety and efficacy outside of these age ranges are insufficient.
3. Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP).
(Minimum age: 6 weeks)
• The fifth dose is not necessary if the fourth dose was administered at age >4 years.
• DTaP is not indicated for persons aged >7 years.
4. Haemophilus influenzae  type b conjugate vaccine (Hib). (Minimum age: 6 weeks)
• Vaccine is not generally recommended for children aged >5 years.
• If current age <12 months and the first 2 doses were PRP-OMP (PedvaxHIB® or
ComVax® [Merck]), the third (and final) dose should be administered at age 12–
15 months and at least 8 weeks after the second dose.
• If first dose was administered at age 7–11 months, administer 2 doses separated
by 4 weeks plus a booster at age 12–15 months.
5. Pneumococcal conjugate vaccine (PCV). (Minimum age: 6 weeks)
• Vaccine is not generally recommended for children aged >5 years.
6. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 weeks)
• For children who received an all-IPV or all-oral poliovirus (OPV) series, a fourth
dose is not necessary if third dose was administered at age >4 years.
• If both OPV and IPV were administered as part of a series, a total of 4 doses
should be administered, regardless of the child’s current age.
7. Measles, mumps, and rubella vaccine (MMR). (Minimum age: 12 months)
• The second dose of MMR is recommended routinely at age 4–6 years but may
be administered earlier if desired.
• If not previously vaccinated, administer 2 doses of MMR during any visit with
>4 weeks between the doses.
8. Varicella vaccine. (Minimum age: 12 months)
• The second dose of varicella vaccine is recommended routinely at age
4–6 years but may be administered earlier if desired.
• Do not repeat the second dose in persons aged <13 years if administered
>28 days after the first dose.
9. Hepatitis A vaccine (HepA). (Minimum age: 12 months)
• HepA is recommended for certain groups of children, including in areas where
vaccination programs target older children. See MMWR 2006;55(No. RR-7):1–23.
10. Tetanus and diphtheria toxoids vaccine (Td) and tetanus and diphtheria
toxoids and acellular pertussis vaccine (Tdap). (Minimum ages: 7 years for
Td, 10 years for BOOSTRIX®, and 11 years for ADACEL™)
• Tdap should be substituted for a single dose of Td in the primary catch-up series
or as a booster if age appropriate; use Td for other doses.
• A 5-year interval from the last Td dose is encouraged when Tdap is used as a
booster dose. A booster (fourth) dose is needed if any of the previous doses
were administered at age <12 months. Refer to ACIP recommendations for further
information. See MMWR 2006;55(No. RR-3).
11. Human papillomavirus vaccine (HPV). (Minimum age: 9 years)
• Administer the HPV vaccine series to females at age 13–18 years if not previously
vaccinated.
The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be
restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child’s age.
Information about reporting reactions after immunization is available online at http://www.vaers.hhs.gov or by telephone via the 24-hour national toll-free information line 800-822-7967.
Suspected cases of vaccine-preventable diseases should be reported to the state or local health department. Additional information, including precautions and contraindications for
immunization, is available from the National Center for Immunization and Respiratory Diseases at http://www.cdc.gov/nip/default.htm or telephone, 800-CDC-INFO (800-232-4636).
